Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
出版年份 2017 全文链接
标题
Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
作者
关键词
-
出版物
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume 32, Issue 3, Pages 355-362
出版商
Wiley
发表日期
2017-11-15
DOI
10.1111/jdv.14695
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis
- (2017) Robert Wolk et al. Journal of Clinical Lipidology
- The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events
- (2017) Alexander Egeberg et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
- (2017) Joseph F. Merola et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK inhibitors in dermatology: The promise of a new drug class
- (2017) William Damsky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of Uveitis Among People With Psoriasis
- (2017) Ching-Chi Chi et al. JAMA Ophthalmology
- Increased airway inflammation in patients with psoriasis
- (2016) G. Damiani et al. BRITISH JOURNAL OF DERMATOLOGY
- Update on the association between interleukin-12 p40 gene polymorphism and risk of psoriasis: A meta-analysis
- (2016) Zigang Zhao et al. Dermatologica Sinica
- Health state utility, willingness to pay, and quality of life among Taiwanese patients with psoriasis
- (2016) Wei-Chih Ko et al. Dermatologica Sinica
- A lack of association between genetic polymorphisms in beta-defensins and susceptibility of psoriasis in Taiwanese: A case–control study
- (2016) Yu-Jui Hsieh et al. Dermatologica Sinica
- Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study
- (2016) Akihiko Asahina et al. JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
- (2016) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis
- (2016) Steven R. Feldman et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study
- (2016) F. Valenzuela et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma
- (2015) M. Malerba et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Impact of psoriasis on quality of life in Taiwan
- (2015) Hui-Ju Yang et al. Dermatologica Sinica
- Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: A nationwide population-based cohort study
- (2015) Ching-Chi Chi et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- An insight into JAK-STAT signalling in dermatology
- (2014) J. A. Palanivel et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system
- (2014) Shu-Hui Wang et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle
- (2014) Ching-Chi Chi et al. Biomed Research International
- Exhaled Nitric Oxide as a Biomarker in COPD and Related Comorbidities
- (2014) Mario Malerba et al. Biomed Research International
- Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity
- (2013) Rosa M. Andrés et al. EXPERIMENTAL DERMATOLOGY
- Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis
- (2013) C. Mamolo et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States
- (2013) April W. Armstrong et al. JAMA Dermatology
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis
- (2012) Howa Yeung et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Definition of treatment goals for moderate to severe psoriasis: a European consensus
- (2010) U. Mrowietz et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice
- (2009) B. Y. Chang et al. JOURNAL OF IMMUNOLOGY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started